Clinical vaccine development for H5N1 influenza

Expert Review of Vaccines

Volumn 12, Issue 7, 2013, Pages 767-777

  Clegg, Christopher H ^a   Rininger, Joseph A ^b   Baldwin, Susan L ^c  

^a TRIA Bioscience Corp   (United States)

^b CaroGen Corporation   (United States)

^c INFECTIOUS DISEASE RESEARCH INSTITUTE   (United States)

Author keywords

adjuvant; dose sparing; emulsion; H5N1; pandemic influenza; recombinant protein; Toll like receptor 4; vaccine

Indexed keywords

ADJUVANT; ALUMINUM SALT; BACTERIUM LIPOPOLYSACCHARIDE; GLUCOPYRANOSYL LIPID; INACTIVATED VACCINE; INFLUENZA VACCINE; ISCOMATRIX; NEUTRALIZING ANTIBODY; OIL IN WATER EMULSION; RECOMBINANT VACCINE; UNCLASSIFIED DRUG;

2009 H1N1 INFLUENZA; ACUTE PHASE RESPONSE; ADAPTIVE IMMUNITY; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN PRESENTING CELL; AVIAN INFLUENZA; CAUSE OF DEATH; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CROSS PRESENTATION; CROSS PROTECTION; DRUG SAFETY; EMULSION; EPIDEMIC; GENETIC REASSORTMENT; HEALTH CARE NEED; HEMAGGLUTINATION INHIBITION; HOSPITALIZATION; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; INFLUENZA A (H5N1); INFLUENZA VIRUS A H5N1; NONHUMAN; PANDEMIC; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RECOMBINANT DNA TECHNOLOGY; REVIEW; RISK MANAGEMENT; SALMONELLA MINNESOTA; SEASONAL INFLUENZA; SEROCONVERSION; VACCINE PRODUCTION; VERO CELL; VIRUS INACTIVATION; VIRUS LIKE AGENT; VIRUS REPLICATION; VIRUS TRANSMISSION;

BIOTECHNOLOGY; DRUG DISCOVERY; HUMANS; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; TECHNOLOGY, PHARMACEUTICAL;

EID: 84880874561     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.2013.811178     Document Type: Review

References (79)

1. Lui KJ, Kendal AP. Impact of influenza epidemics on mortality in the United States from October 1972 to May 1985. Am. J. Public Health 77(6), 712-716 (1987
2. Bosch FX, Garten W, Klenk HD, Rott R. Proteolytic cleavage of influenza virus hemagglutinins: Primary structure of the connecting peptide between HA1 and HA2 determines proteolytic cleavability and pathogenicity of avian influenza viruses. Virology 113(2), 725-735 (1981
3. Stephenson I. H5N1 vaccines: How prepared are we for a pandemic? Lancet 368(9540), 965-966 (2006
4. Keitel WA, Atmar RL. Preparing for a possible pandemic: Influenza A/H5N1 vaccine development. Curr. Opin. Pharmacol. 7(5), 484-490 (2007
5. Poland GA, Jacobson RM, Targonski PV. Avian and pandemic influenza: An overview. Vaccine 25(16), 3057-3061 (2007
6. WHO/World Organisation for Animal Health/Food and Agriculture Organization H5N1 Evolution Working Group. Toward a unified nomenclature system for highly pathogenic avian influenza virus (H5N1) [conference summary]. Emerg. Infect. Dis. [serial on the Internet] 14(7) (2008
7. Herfst S, Schrauwen EJ, Linster M et al. Airborne transmission of influenza A/ H5N1 virus between ferrets. Science 336(6088), 1534-1541 (2012
8. Imai M, Watanabe T, Hatta M et al. Experimental adaptation of an influenza H5 HA confers respiratory droplet transmission to a reassortant H5 HA/ H1N1 virus in ferrets. Nature 486(7403), 420-428 (2012
9. Raviv Y, Blumenthal R, Tompkins SM, Humberd J, Hogan RJ, Viard M. Hydrophobic inactivation of influenza viruses confers preservation of viral structure with enhanced immunogenicity. J. Virol. 82(9), 4612-4619 (2008
10. Hovden AO, Cox RJ, Haaheim LR. Whole influenza virus vaccine is more immunogenic than split influenza virus vaccine and induces primarily an IgG2a response in BALB/c mice. Scand. J. Immunol. 62(1), 36-44 (2005
11. Fritz R, Sabarth N, Kiermayr S et al. A Vero cell-derived whole-virus H5N1 vaccine effectively induces neuraminidaseinhibiting antibodies. J. Infect. Dis. 205(1), 28-34 (2012
12. Suguitan AL Jr, Marino MP, Desai PD et al. The influence of the multi-basic cleavage site of the H5 hemagglutinin on the attenuation, immunogenicity and efficacy of a live attenuated influenza A H5N1 cold-Adapted vaccine virus. Virology 395(2), 280-288 (2009
13. Steel J. New strategies for the development of H5N1 subtype influenza vaccines: Progress and challenges. BioDrugs 25(5), 285-298 (2011
14. Keating GM, Plosker GL, Lyseng-Williamson KA. A/H5N1 prepandemic influenza vaccine (Vepacel®): A guide to its use. BioDrugs 26(6), 425-430 (2012
15. Cancro MP, Hao Y, Scholz JL et al. B cells and aging: Molecules and mechanisms. Trends Immunol. 30(7), 313-318 (2009
16. Marrack P, McKee AS, Munks MW. Towards an understanding of the adjuvant action of aluminium. Nat. Rev. Immunol. 9(4), 287-293 (2009
17. Wang Y, Rahman D, Lehner T. A comparative study of stress-mediated immunological functions with the adjuvanticity of alum. J. Biol. Chem. 287(21), 17152-17160 (2012
18. Martinon F, Mayor A, Tschopp J. The inflammasomes: Guardians of the body. Annu. Rev. Immunol. 27, 229-265 (2009
19. Flach TL, Ng G, Hari A et al. Alum interaction with dendritic cell membrane lipids is essential for its adjuvanticity. Nat. Med. 17(4), 479-487 (2011
20. McKee AS, Burchill MA, Munks MW et al. Host DNA released in response to aluminum adjuvant enhances MHC class II-mediated antigen presentation and prolongs CD4 T-cell interactions with dendritic cells. Proc. Natl Acad. Sci. USA 110(12), E1122-E1131 (2013
21. O'Hagan DT, Tsai T, Reed S. Emulsionbased adjuvants for improved influenza vaccine. In: Influenza Vaccines for the Future. Del Giudice G, Rappuoli R (Eds). Springer Basel AG, 327-358 (2011
22. Klucker MF, Dalençon F, Probeck P, Haensler J. AF03, an alternative squalene emulsion-based vaccine adjuvant prepared by a phase inversion temperature method. J. Pharm. Sci. 101(12), 4490-4500 (2012
23. O'Hagan DT, Ott GS, De Gregorio E, Seubert A. The mechanism of action of MF59 -An innately attractive adjuvant formulation. Vaccine 30(29), 4341-4348 (2012
24. Galli G, Hancock K, Hoschler K et al. Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccine. Proc. Natl Acad. Sci. USA 106(19), 7962-7967 (2009
25. Banzhoff A, Gasparini R, Laghi-Pasini F et al. MF59-Adjuvanted H5N1 vaccine induces immunologic memory and heterotypic antibody responses in non-elderly and elderly adults. PLoS ONE 4(2), e4384 (2009
26. Schwarz TF, Horacek T, Knuf M et al. Single dose vaccination with AS03-Adjuvanted H5N1 vaccines in a randomized trial induces strong and broad immune responsiveness to booster vaccination in adults. Vaccine 27(45), 6284-6290 (2009
27. Leroux-Roels I, Roman F, Forgus S et al. Priming with AS03 A-Adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: An open non-randomised extension of a double-blind randomised primary study. Vaccine 28(3), 849-857 (2010
28. Levie K, Leroux-Roels I, Hoppenbrouwers K et al. An adjuvanted, low-dose, pandemic influenza A (H5N1) vaccine candidate is safe, immunogenic, and induces crossreactive immune responses in healthy adults. J. Infect. Dis. 198(5), 642-649 (2008
29. Leroux-Roels I, Bernhard R, Gé;rard P, Dramé; M, Hanon E, Leroux-Roels G. Broad Clade 2 cross-reactive immunity induced by an adjuvanted clade 1 rH5N1 pandemic influenza vaccine. PLoS ONE 3(2), e1665 (2008
30. Galli G, Medini D, Borgogni E et al. Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-Term persistence of protective antibody levels. Proc. Natl Acad. Sci. USA 106(10), 3877-3882 (2009
31. Khurana S, Verma N, Yewdell JW et al. MF59 adjuvant enhances diversity and affinity of antibody-mediated immune response to pandemic influenza vaccines. Sci. Transl. Med. 3(85), 85ra48 (2011
32. Vesikari T, Karvonen A, Tilman S et al. Immunogenicity and safety of MF59-Adjuvanted H5N1 influenza vaccine from infancy to adolescence. Pediatrics 126(4), e762-e770 (2010
33. Dormitzer PR, Galli G, Castellino F et al. Influenza vaccine immunology. Immunol. Rev. 239(1), 167-177 (2011
34. Kannanganat S, Ibegbu C, Chennareddi L, Robinson HL, Amara RR. Multiplecytokine-producing antiviral CD4 T cells are functionally superior to single-cytokine-producing cells. J. Virol. 81(16), 8468-8476 (2007
35. McKinstry KK, Strutt TM, Swain SL. Hallmarks of CD4 T cell immunity against influenza. J. Intern. Med. 269(5), 507-518 (2011
36. Reed SG, Bertholet S, Coler RN, Friede M. New horizons in adjuvants for vaccine development. Trends Immunol. 30(1), 23-32 (2009
37. Duthie MS, Windish HP, Fox CB, Reed SG. Use of defined TLR ligands as adjuvants within human vaccines. Immunol. Rev. 239(1), 178-196 (2011
38. Shen H, Tesar BM, Walker WE, Goldstein DR. Dual signaling of MyD88 and TRIF is critical for maximal TLR4-induced dendritic cell maturation. J. Immunol. 181(3), 1849-1858 (2008
39. McKeage K, Romanowski B. AS04-Adjuvanted human papillomavirus (HPV) types 16 and 18 vaccine (Cervarix®): A review of its use in the prevention of premalignant cervical lesions and cervical cancer causally related to certain oncogenic HPV types. Drugs 71(4), 465-488 (2011
40. Hagen SR, Thompson JD, Snyder DS, Myers KR. Analysis of a monophosphoryl lipid A immunostimulant preparation from Salmonella minnesota R595 by high-performance liquid chromatography. J. Chromatogr. A 767(1-2), 53-61 (1997
41. Rallabhandi P, Awomoyi A, Thomas KE et al. Differential activation of human TLR4 by Escherichia coli and Shigella flexneri 2a lipopolysaccharide: Combined effects of lipid A acylation state and TLR4 polymorphisms on signaling. J. Immunol. 180(2), 1139-1147 (2008
42. Coler RN, Bertholet S, Moutaftsi M et al. Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant. PLoS ONE 6(1), e16333 (2011
43. Baldwin SL, Shaverdian N, Goto Y et al. Enhanced humoral and Type 1 cellular immune responses with Fluzone adjuvanted with a synthetic TLR4 agonist formulated in an emulsion. Vaccine 27(43), 5956-5963 (2009
44. Coler RN, Baldwin SL, Shaverdian N et al. A synthetic adjuvant to enhance and expand immune responses to influenza vaccines. PLoS ONE 5(10), e13677 (2010
45. Behzad H, Huckriede AL, Haynes L et al. GLA-SE, a synthetic toll-like receptor 4 agonist, enhances T-cell responses to influenza vaccine in older adults. J. Infect. Dis. 205(3), 466-473 (2012
46. Morelli AB, Becher D, Koernig S, Silva A, Drane D, Maraskovsky E. ISCOMATRIX: A novel adjuvant for use in prophylactic and therapeutic vaccines against infectious diseases. J. Med. Microbiol. 61(Pt 7), 935-943 (2012
47. Middleton D, Rockman S, Pearse M et al. Evaluation of vaccines for H5N1 influenza virus in ferrets reveals the potential for protective single-shot immunization. J. Virol. 83(15), 7770-7778 (2009
48. Sambhara S, Poland GA. H5N1 Avian influenza: Preventive and therapeutic strategies against a pandemic. Annu. Rev. Med. 61, 187-198 (2010
49. Bernard A, Payton M, Radford KR. Protein expression in the baculovirus system. Curr. Protoc. Protein Sci. Chapter 5, Unit 5.5 (2001
50. Feshchenko E, Rhodes DG, Felberbaum R et al. Pandemic influenza vaccine: Characterization of A/California/07/2009 (H1N1) recombinant hemagglutinin protein and insights into H1N1 antigen stability. BMC Biotechnol. 12, 77 (2012
51. Treanor JJ, Wilkinson BE, Masseoud F et al. Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans. Vaccine 19(13-14), 1732-1737 (2001
52. Kanazashi S. A Phase I/II clinical study of UMN-0501 for healthy adult males. Presented at: The 5th WHO Meeting on Evaluation of Pandemic Influenza Prototype Vaccines in Clinical Trials (2009
53. Clegg CH, Roque R, Van Hoeven N et al. Adjuvant solution for pandemic influenza vaccine production. Proc. Natl Acad. Sci. USA 109(43), 17585-17590 (2012
54. D'Aoust MA, Couture MM, Charland N et al. The production of hemagglutininbased virus-like particles in plants: A rapid, efficient and safe response to pandemic influenza. Plant Biotechnol. J. 8(5), 607-619 (2010
55. Chichester JA, Jones RM, Green BJ et al. Safety and immunogenicity of a plantproduced recombinant hemagglutininbased influenza vaccine (HAI-05) derived from A/Indonesia/05/2005 (H5N1) influenza virus: A phase 1 randomized, double-blind, placebo-controlled, dose-escalation study in healthy adults. Viruses 4(11), 3227-3244 (2012
56. Liu G, Song L, Reiserova L et al. Flagellin-HA vaccines protect ferrets and mice against H5N1 highly pathogenic avian influenza virus (HPAIV) infections. Vaccine 30(48), 6833-6838 (2012
57. Taylor DN, Treanor JJ, Sheldon EA et al. Development of VAX128, a recombinant hemagglutinin (HA) influenza-flagellin fusion vaccine with improved safety and immune response. Vaccine 30(39), 5761-5769 (2012
58. Report of the 7th meeting on Evaluation of Pandemic Influenza Vaccines in Clinical Trials. WHO, Geneva, Switzerland, 17-18 February 2011. Vaccine 29, 7579-7586 (2011
59. Khurana S, Verma S, Verma N et al. Bacterial HA1 vaccine against pandemic H5N1 influenza virus: Evidence of oligomerization, hemagglutination, and cross-protective immunity in ferrets. J. Virol. 85(3), 1246-1256 (2011
60. Khurana S, Wu J, Verma N et al. H5N1 virus-like particle vaccine elicits crossreactive neutralizing antibodies that preferentially bind to the oligomeric form of influenza virus hemagglutinin in humans. J. Virol. 85(21), 10945-10954 (2011
61. Mahmood K, Bright RA, Mytle N et al. H5N1 VLP vaccine induced protection in ferrets against lethal challenge with highly pathogenic H5N1 influenza viruses. Vaccine 26(42), 5393-5399 (2008
62. Bright RA, Carter DM, Crevar CJ et al. Cross-clade protective immune responses to influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particle. PLoS ONE 3(1), e1501 (2008
63. Landry N, Ward BJ, Tré;panier S et al. Preclinical and clinical development of plant-made virus-like particle vaccine against avian H5N1 influenza. PLoS ONE 5(12), e15559 (2010
64. Landry N. Clinical development of plant-made influenza VLP vaccines. Presented at: 7th WHO Meeting on Evaluation of Pandemic Influenza Vaccines in Clinical Trials. Geneva, Switzerland 17-18 February (2011
65. Ahmed SS, Plotkin SA, Black S, Coffman RL. Assessing the safety of adjuvanted vaccines. Sci. Transl. Med. 3(93), 93rv2 (2011
66. Sun Y, Gruber M, Matsumoto M. Overview of global regulatory toxicology requirements for vaccines and adjuvants. J. Pharmacol. Toxicol. Methods 65(2), 49-57 (2012
67. Lippi G, Targher G, Franchini M. Vaccination, squalene and anti-squalene antibodies: Facts or fiction? Eur. J. Intern. Med. 21(2), 70-73 (2010
68. Pellegrini M, Nicolay U, Lindert K, Groth N, Della Cioppa G. MF59-Adjuvanted versus non-Adjuvanted influenza vaccines: Integrated analysis from a large safety database. Vaccine 27(49), 6959-6965 (2009
69. Wijnans L, Lecomte C, de Vries C et al. The incidence of narcolepsy in Europe: Before, during, and after the influenza A(H1N1)pdm09 pandemic and vaccination campaigns. Vaccine 31(8), 1246-1254 (2013
70. Kothare SV, Wiznitzer M. Association between H1N1 vaccination and narcolepsycataplexy: Flu to sleep. Neurology 80(14), 1276-1277 (2013
71. Edwards KM, Sabow A, Pasternak A, Boslego JW. Strategies for broad global access to pandemic influenza vaccines. Curr. Top. Microbiol. Immunol. 333, 471-493 (2009
72. Treanor JJ, Campbell JD, Zangwill KM, Rowe T, Wolff M. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N. Engl. J. Med. 354(13), 1343-1351 (2006
73. Bresson JL, Perronne C, Launay O et al. Safety and immunogenicity of an inactivated split-virion influenza A/ Vietnam/1194/2004 (H5N1) vaccine: Phase I randomised trial. Lancet 367(9523), 1657-1664 (2006
74. Bernstein DI, Edwards KM, Dekker CL et al. Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults. J. Infect. Dis. 197(5), 667-675 (2008
75. Beran J, Abdel-Messih IA, Raupachova J, Hobzova L, Fragapane E. A phase III, randomized, open-label study to assess the tolerability and immunogenicity of an H5N1 influenza vaccine administered to healthy adults with a 1-, 2-, 3-, or 6-week interval between first and second doses. Clin. Ther. 32(13), 2186-2197 (2010
76. Leroux-Roels I, Borkowski A, Vanwolleghem T et al. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: A randomised controlled trial. Lancet 370(9587), 580-589 (2007
77. Thongcharoen P, Auewarakul P, Hutagalung Y et al. Cross-clade immunogenicity and antigen-sparing with an AS03(A)-Adjuvanted prepandemic influenza vaccine in a Thai population. J. Med. Assoc. Thai. 94(8), 916-926 (2011
78. Nolan TM, Richmond PC, Skeljo MV et al. Phase I and II randomised trials of the safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in healthy adults. Vaccine 26(33), 4160-4167 (2008
79. Treanor JJ, Izikson R, Dunkle L et al. Safety and immunogenicity of a recombinant hemagglutinin (rHA) pandemic H5N1 influenza vaccine. Presented at: 52nd ICAAC. San Francisco, CA, USA (2012